Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Preferred Shares Issued: 2017-2018

Historic Preferred Shares Issued for Crinetics Pharmaceuticals (CRNX) over the last 1 years, with Dec 2018 value amounting to $9,000.

  • Crinetics Pharmaceuticals' Preferred Shares Issued fell 99.88% to $9,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $70.5 million, marking a year-over-year change of. This contributed to the annual value of $63.3 million for FY2018, which is 428.66% up from last year.
  • As of Q4 2018, Crinetics Pharmaceuticals' Preferred Shares Issued stood at $9,000, which was up 107.09% from -$127,000 recorded in Q2 2018.
  • In the past 5 years, Crinetics Pharmaceuticals' Preferred Shares Issued registered a high of $63.4 million during Q1 2018, and its lowest value of -$127,000 during Q2 2018.
  • Over the past 2 years, Crinetics Pharmaceuticals' median Preferred Shares Issued value was $3.6 million (recorded in 2017), while the average stood at $17.6 million.
  • Data for Crinetics Pharmaceuticals' Preferred Shares Issued shows a maximum YoY slumped of 99.88% (in 2018) over the last 5 years.
  • Quarterly analysis of 2 years shows Crinetics Pharmaceuticals' Preferred Shares Issued stood at $7.2 million in 2017, then tumbled by 99.88% to $9,000 in 2018.
  • Its Preferred Shares Issued was $9,000 in Q4 2018, compared to -$127,000 in Q2 2018 and $63.4 million in Q1 2018.